What is the share price of Eris Lifesciences Ltd (ERIS) today?
The share price of ERIS as on 15th July 2025 is ₹1754.30. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Eris Lifesciences Ltd (ERIS) share?
The past returns of Eris Lifesciences Ltd (ERIS) share are- Past 1 week: 1.53%
- Past 1 month: -4.00%
- Past 3 months: 26.96%
- Past 6 months: 34.92%
- Past 1 year: 72.79%
- Past 3 years: 160.05%
- Past 5 years: 296.72%
What are the peers or stocks similar to Eris Lifesciences Ltd (ERIS)?
The peers or stocks similar to Eris Lifesciences Ltd (ERIS) include:What is the dividend yield % of Eris Lifesciences Ltd (ERIS) share?
The current dividend yield of Eris Lifesciences Ltd (ERIS) is 0.42.What is the market cap of Eris Lifesciences Ltd (ERIS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Eris Lifesciences Ltd (ERIS) is ₹23786.86 Cr as of 15th July 2025.What is the 52 week high and low of Eris Lifesciences Ltd (ERIS) share?
The 52-week high of Eris Lifesciences Ltd (ERIS) is ₹1910 and the 52-week low is ₹987.10.What is the PE and PB ratio of Eris Lifesciences Ltd (ERIS) stock?
The P/E (price-to-earnings) ratio of Eris Lifesciences Ltd (ERIS) is 67.61. The P/B (price-to-book) ratio is 7.27.Which sector does Eris Lifesciences Ltd (ERIS) belong to?
Eris Lifesciences Ltd (ERIS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Eris Lifesciences Ltd (ERIS) shares?
You can directly buy Eris Lifesciences Ltd (ERIS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Eris Lifesciences Ltd
ERIS Share Price
ERIS Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ERIS Performance & Key Metrics
ERIS Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
67.51 | 7.27 | 0.42% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
37.43 | 6.45 | 0.81% |
from 10 analysts
Price Upside
Earnings Growth
Rev. Growth
ERIS Company Profile
Eris Lifesciences Limited is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian Pharmaceutical Market
ERIS Forecast
ERIS Forecasts
Price
Revenue
Earnings
ERIS Share Price Forecast
ERIS Share Price Forecast
All values in ₹
All values in ₹
ERIS Company Revenue Forecast
ERIS Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
ERIS Stock EPS (Earnings Per Share) Forecast
ERIS Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
ERIS
ERIS
Income
Balance Sheet
Cash Flow
ERIS Income Statement
ERIS Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 774.61 | 882.01 | 1,013.85 | 1,089.46 | 1,220.57 | 1,373.13 | 1,743.83 | 2,080.11 | 2,926.99 | 2,912.06 | ||||||||||
Raw Materials | 107.73 | 136.92 | 167.12 | 150.12 | 276.44 | 259.29 | 348.53 | 379.33 | 749.46 | 1,876.44 | ||||||||||
Power & Fuel Cost | 3.02 | 3.17 | 3.45 | 4.62 | 3.95 | 4.16 | 5.70 | 12.04 | 15.08 | |||||||||||
Employee Cost | 131.22 | 157.32 | 190.66 | 205.69 | 229.30 | 250.18 | 346.16 | 403.82 | 505.09 | |||||||||||
Selling & Administrative Expenses | 204.42 | 224.28 | 279.66 | 238.82 | 210.94 | 256.10 | 375.66 | 422.92 | 476.96 | |||||||||||
Operating & Other expenses | 33.97 | 11.81 | -3.80 | 106.30 | 60.49 | 92.28 | 119.88 | 163.35 | 144.78 | |||||||||||
EBITDA | 294.25 | 348.51 | 376.76 | 383.91 | 439.45 | 511.12 | 547.90 | 698.65 | 1,035.62 | 1,035.62 | ||||||||||
Depreciation/Amortization | 22.76 | 25.64 | 36.35 | 50.26 | 42.99 | 64.71 | 117.09 | 182.51 | 315.46 | 314.67 | ||||||||||
PBIT | 271.49 | 322.87 | 340.41 | 333.65 | 396.46 | 446.41 | 430.81 | 516.14 | 720.16 | 720.95 | ||||||||||
Interest & Other Items | 1.10 | 10.65 | 23.06 | 2.30 | 1.98 | 4.22 | 26.17 | 84.80 | 231.29 | 231.29 | ||||||||||
PBT | 270.39 | 312.22 | 317.35 | 331.35 | 394.48 | 442.19 | 404.64 | 431.34 | 488.87 | 489.66 | ||||||||||
Taxes & Other Items | 23.60 | 18.12 | 26.56 | 34.86 | 39.36 | 36.08 | 22.48 | 39.29 | 137.03 | 137.29 | ||||||||||
Net Income | 246.79 | 294.10 | 290.79 | 296.49 | 355.12 | 406.11 | 382.16 | 392.05 | 351.84 | 352.37 | ||||||||||
EPS | 17.95 | 21.39 | 21.15 | 21.70 | 26.15 | 29.89 | 28.11 | 28.83 | 25.85 | 25.88 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 2.87 | 5.50 | 6.01 | 7.35 | 0.00 | 7.35 | 7.35 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.13 | 0.21 | 0.20 | 0.26 | 0.00 | 0.28 | 0.28 |
ERIS Company Updates
ERIS Stock Peers
ERIS Past Performance & Peer Comparison
ERIS Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Eris Lifesciences Ltd | 67.61 | 7.27 | 0.42% |
Sun Pharmaceutical Industries Ltd | 36.94 | 5.57 | 0.95% |
Cipla Ltd | 22.73 | 3.83 | 1.08% |
Torrent Pharmaceuticals Ltd | 60.29 | 15.18 | 0.94% |
ERIS Stock Price Comparison
Compare ERIS with any stock or ETFERIS Holdings
ERIS Shareholdings
ERIS Promoter Holdings Trend
ERIS Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
ERIS Institutional Holdings Trend
ERIS Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
ERIS Shareholding Pattern
ERIS Shareholding Pattern
ERIS Shareholding History
ERIS Shareholding History
Mutual Funds Invested in ERIS
Mutual Funds Invested in ERIS
No mutual funds holding trends are available
Top 5 Mutual Funds holding Eris Lifesciences Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 4.0638% | Percentage of the fund’s portfolio invested in the stock 2.84% | Change in the portfolio weight of the stock over the last 3 months 0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 6/89 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.7411% | Percentage of the fund’s portfolio invested in the stock 1.67% | Change in the portfolio weight of the stock over the last 3 months 0.17% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 17/123 (+46) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3215% | Percentage of the fund’s portfolio invested in the stock 2.25% | Change in the portfolio weight of the stock over the last 3 months 0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 6/106 (0) |
Compare 3-month MF holding change on Screener
smallcases containing ERIS stock
smallcases containing ERIS stock
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Eris Lifesciences Ltd
ERIS Events
ERIS Events
ERIS Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
ERIS Dividend Trend
No dividend trend available
ERIS Upcoming Dividends
ERIS Upcoming Dividends
No upcoming dividends are available
ERIS Past Dividends
ERIS Past Dividends
Cash Dividend
Ex DateEx DateFeb 13, 2025
Dividend/Share
₹7.35
Ex DateEx Date
Feb 13, 2025
Cash Dividend
Ex DateEx DateAug 11, 2022
Dividend/Share
₹7.35
Ex DateEx Date
Aug 11, 2022
Cash Dividend
Ex DateEx DateAug 5, 2021
Dividend/Share
₹6.01
Ex DateEx Date
Aug 5, 2021
Cash Dividend
Ex DateEx DateAug 13, 2020
Dividend/Share
₹5.50
Ex DateEx Date
Aug 13, 2020
Cash Dividend
Ex DateEx DateMar 19, 2020
Dividend/Share
₹2.87
Ex DateEx Date
Mar 19, 2020
ERIS Stock News & Opinions
ERIS Stock News & Opinions
ERIS Lifesciences announced that the 19th Annual General Meeting(AGM) of the company will be held on 25 July 2025.Powered by Capital Market - Live
Profit before tax (PBT) climbed 67.9% YoY to Rs 128.87 crore in Q4 FY25. During the quarter EBITDA stood at Rs 252 crore, up 70% compared with Rs 148 crore posted in same quarter last year. EBITDA margin expanded to 35.8% in Q4 FY25 as against 26.9% in Q4 FY24. Revenue from domestic branded formulation (DBF) business jumped 25% YoY to Rs 602 crore in Q4 FY25. The organic base grew 10% to Rs 529 crore, while revenue from Biocon -2 stood at Rs 73 crore during the period under review. The company reported 22% organic growth in overall insulin revenue to Rs 300 crore despite significant product shortage in RHI throughout the year. On full year basis, the company's consolidated net profit declined 10.3% to Rs 351.84 crore on 44.6% increase in revenue from operations to Rs 2,879.26 crore in FY25 over FY24. On guidance front, for FY26, the company projects an annual revenue addition of Rs 200'300 crore to its overall insulin franchise, beginning October 2025, driven by the insourcing of insulin production at its Bhopal facility. This strategic move is expected to significantly enhance its insulin portfolio. In DBF business, the company anticipates revenue growth of 15% to 21%, translating to revenues in the range of Rs 2,900'3,050 crore. EBITDA for the segment is projected between Rs 1,070 crore and Rs 1,130 crore, with EBITDA margins maintained around 37%. Additionally, the company expects revenues from its Swiss Parentals division to range between Rs 375- 390 crore reflecting a growth of 15'20%. EBITDA for this segment is estimated between Rs 130 crore and Rs 135 crore, with an EBITDA margin of approximately 35%. The company plans to expand Eris-AMD, its new injectable facility, with a capital expenditure of Rs 100- 200 crore in FY26. Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products.Powered by Capital Market - Live
The key equity indices traded with limited losses in morning trade as investors engaged in mild profit booking despite supportive global cues. The Nifty traded below the 24,900 level. Market participants will closely monitor global trade developments and the ongoing Q4 earnings season, which are likely to influence sentiment in the coming days. Realty shares witnessed buying demand for fifth consecutive trading session. At 10:25 IST, the barometer index, the S&P BSE Sensex, declined 207.05 points or 0.25% to 81,852.37. The Nifty 50 index fell 44.90 points or 0.19% to 24,894.40. The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index fell 0.27% and the S&P BSE Small-Cap index shed 0.06%. The market breadth was positive. On the BSE, 1,772 shares rose and 1,729 shares fell. A total of 207 shares were unchanged. Buzzing Index: The Nifty Realty index advanced 1% to 942.55. The index rose 8.8% in the five consecutive trading sessions. DLF (up 5.29%), Raymond (up 4.95%), Sobha (up 0.55%), Prestige Estates Projects (up 0.36%) and Godrej Properties (up 0.09%) advanced. On the other hand, Phoenix Mills (down 1.16%), Macrotech Developers (down 1.01%) and Brigade Enterprises (down 0.91%) declined Stocks in Spotlight: Eris Lifesciences rallied 3.53% after the company reported a 30.29% jump in consolidated net profit to Rs 92.01 crore on 28.38% increase in revenue from operations to Rs 702.60 crore in Q4 FY25 over Q4 FY24. Ashok Leyland added 1.18% after the company's board is scheduled to meet on 23 May to consider the proposal for the issue of bonus shares. Adani Ports & Special Economic Zone (APSEZ) shed 0.18%. The company's board will meet on 23 May to consider issuing non-convertible debentures (NCDs) via a private placement basis.Powered by Capital Market - Live
Net profit of ERIS Lifesciences rose 32.11% to Rs 93.84 crore in the quarter ended March 2025 as against Rs 71.03 crore during the previous quarter ended March 2024. Sales rose 28.38% to Rs 702.60 crore in the quarter ended March 2025 as against Rs 547.27 crore during the previous quarter ended March 2024. For the full year,net profit declined 10.26% to Rs 351.84 crore in the year ended March 2025 as against Rs 392.05 crore during the previous year ended March 2024. Sales rose 44.59% to Rs 2879.26 crore in the year ended March 2025 as against Rs 1991.30 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales702.60547.27 28 2879.261991.30 45 OPM %35.9227.12 -35.3333.89 - PBDT206.12130.55 58 804.33613.85 31 PBT128.8776.75 68 488.87431.34 13 NP93.8471.03 32 351.84392.05 -10 Powered by Capital Market - Live
ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 19 May 2025.Powered by Capital Market - Live
Eris Lifesciences has allotted 33,287 equity shares under ESOP on 06 March 2025. The paid-up share capital of the Company accordingly stands increased from Rs. 13,61,29,282/- (13,61,29,282 equity shares of Re. 1/- each) to Rs. 13,61,62,569/- (13,61,62,569 equity shares of Re. 1/- each). Powered by Capital Market - Live
Eris Lifesciences has availed credit facilities amounting to Rs 1000 crore from Kotak Mahindra Bank (Bank). The aggregate debt level of the company would remain unchanged.Powered by Capital Market - Live
ERIS Lifesciences announced that the Board of Directors of the Company at its meeting held on 06 February 2025, has recommended a Interim dividend of Rs.7.35 per share (i.e.735%), subject to the approval of the shareholders.Powered by Capital Market - Live
ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 7 February 2025.Powered by Capital Market - Live
Net profit of ERIS Lifesciences declined 18.60% to Rs 83.63 crore in the quarter ended December 2024 as against Rs 102.74 crore during the previous quarter ended December 2023. Sales rose 49.36% to Rs 722.12 crore in the quarter ended December 2024 as against Rs 483.48 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales722.12483.48 49 OPM %34.6636.30 - PBDT197.36161.59 22 PBT116.16115.87 0 NP83.63102.74 -19 Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 21.85%, vs industry avg of 10.15%
Over the last 5 years, market share increased from 0.43% to 0.7%
Over the last 5 years, net income has grown at a yearly rate of 3.48%, vs industry avg of 20.04%